SCHEMBL4053433

SCHEMBL4053433

Nc1ccc(-c2ccncc2)c(-c2cccc(F)c2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 6/20 0.63
ADORA2A P29274 8/20 0.58
ADORA1 P30542 5/20 0.58
ADORA3 P0DMS8 2/20 0.58
MAPK13 O15264 2/20 0.49
MAPK12 P53778 2/20 0.49
MAPK11 Q15759 2/20 0.49
MAPK14 Q16539 2/20 0.49
RAF1 P04049 1/20 0.49
TP53 P04637 1/20 0.47
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP17A1 P05093 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
MTOR P42345 1/20 0.42
DPP4 P27487 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053436 0.86 ADORA2B (0.60) ADORA2BADORA2AADORA1ADORA3MAPK13
SCHEMBL4049728 0.82 ADORA2A (0.52) ADORA2BADORA2AADORA1ADORA3MAPK13
SCHEMBL4059867 0.81 ADORA2A (0.51) ADORA2BADORA2AADORA1ADORA3MAPK13
SCHEMBL18039107 0.81 ADORA2B (0.68) ADORA2BADORA2AADORA1MAPK13MAPK12
SCHEMBL5447978 0.80 ADORA1 (0.69) ADORA2BADORA2AADORA1ADORA3MAPK13
SCHEMBL3057933 0.80 MAPK14 (0.55) ADORA2BADORA2AADORA1ADORA3MAPK13
SCHEMBL3068200 0.78 ADORA2A (0.48) ADORA2BADORA2AADORA1ADORA3MAPK13
SCHEMBL18039068 0.77 ADORA2B (0.57) ADORA2BADORA2AADORA1MEN1CYP3A4
SCHEMBL4052370 0.77 ADORA2A (0.47) ADORA2BADORA2AADORA1ADORA3MAPK13
SCHEMBL6765596 0.77 ADORA1 (0.49) ADORA2BADORA2AADORA1ADORA3MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1446202-A 2-aminopyridine compounds and use thereof as drugs EISAI CO LTD (JP) 2003-10-01 CN claimed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
EP-1735310-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2006-12-27 EP disclosed
WO-2005100353-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA, SA (ES) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA1 ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.